Advanced Squamous Non-Small Cell Lung Cancer: Case 2

Video

Advanced Squamous Non-Small Cell Lung Cancer

March 2017

  • A 70-year-old female presents with shortness of breath and right-sided chest pain of 3 months’ duration
  • She has a 25-year (1-pack/day) smoking history
  • Chest X-ray revealed a pathologic fracture of the right 4th rib and a large right-sided pleural effusion
  • CT scan confirmed the presence of a 3 cm spiculated mass in the right upper lobe, moderate right pleural effusion, and multiple lytic lesions in the spine and ribs
  • Core needle biopsy of the lung mass was performed
    • Pathology showed poorly differentiated lung squamous cell carcinoma, p63+ and CK5/6+ with abundant cytokeratin
    • Genetic testing was negative for known driver mutations
    • PD-L1 testing by IHC showed expression in 20% of cells
  • The patient received palliative radiation therapy to the rib
  • Options for systemic therapy are under discussion
Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
Treating Rare Driver Mutations in NSCLC: EGFR Exon 20 Insertions

Treating Rare Driver Mutations in NSCLC: EGFR Exon 20 Insertions

April 24th 2024
Article

During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.

Read More

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

March 15th 2024
Podcast

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Listen

FDA Approves Adjuvant Alectinib in ALK+ NSCLC

FDA Approves Adjuvant Alectinib in ALK+ NSCLC

April 18th 2024
Article

The FDA approved adjuvant alectinib following tumor resection for the treatment of patients with ALK-positive non-small cell lung cancer.

Read More

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

December 15th 2023
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Listen

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024
Article

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Read More

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

April 12th 2024
Article

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

Read More